Across TCGA pan-cancer cohorts, DEFB116 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated DEFB116 data layer compared with 12 for mass-spec protein.
The strongest signal is observed in small cell lung cancer (SCLC), where higher DEFB116 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DEFB116 expression acts as an unfavorable survival marker.
SCLC, CESC, and UCEC are the cancer types where DEFB116 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.